Requires notification by a prescriber or pharmacist of the substitution of one generic drug product for another generic drug product; requires both oral and written notification.
Requires notification by a prescriber or pharmacist of the substitution of one generic drug product for another generic drug product; requires both oral and written notification.
Requires that pharmacists get express written consent before substituting a drug product for a less expensive drug product, including biological products.
Prohibits a pharmacist from substituting any anti-epileptic drug for the prescribed anti-epileptic drug without notification of and the informed consent of the prescriber and patient or such patient's parent, guardian or spouse.
Requires insurers to cover the substitution of a brand name prescription drug when the federal food and drug administration has declared that there is a supply issue with a generic drug.
Establishes a generic drug research and development laboratory and production facility to manufacture generic prescription drugs in the state and the empire state biosimilar insulin initiative, which will develop generic forms of the three most widely used forms of insulin.